Dovato is owned by Viiv Hlthcare.
Dovato contains Dolutegravir Sodium; Lamivudine.
Dovato has a total of 3 drug patents out of which 0 drug patents have expired.
Dovato was authorised for market use on 08 April, 2019.
Dovato is available in tablet;oral dosage forms.
Dovato can be used as treatment of hiv infection.
The generics of Dovato are possible to be released after 24 January, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11234985 | VIIV HLTHCARE | Antiviral therapy |
Jan, 2031
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Aug 6, 2023 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
48
United States
22
Japan
18
European Union
12
Spain
11
Korea, Republic of
10
Hungary
10
Australia
9
Slovenia
9
Denmark
9
Mexico
8
Poland
8
Canada
8
Hong Kong
8
Portugal
8
Israel
7
Lithuania
7
Norway
6
EA
6
Cyprus
5
China
5
New Zealand
4
Brazil
4
Singapore
3
Philippines
3
Luxembourg
3
Taiwan
3
Morocco
3
RS
3
Croatia
3
South Africa
2
ME
2
Peru
2
Dominican Republic
2
Ukraine
2
Netherlands
2
Russia
1
Chile
1
Viet Nam
1
Costa Rica
1
Turkey
1
Malaysia
1
AP
1
Colombia
1
San Marino
1
Austria
1
Ecuador
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic